“It’s a Way of Reparations”: Why Henrietta Lacks Settlement Matters for Bioethics & Racial Justice
By Amy Goodman,
Democracy Now!
| 08. 07. 2023
The family of Henrietta Lacks, a Black cancer patient whose cells were taken by Johns Hopkins University Hospital without her consent in 1951, has reached a deal over the unethical use of her cells with pharmaceutical company Thermo Fisher Scientific. Henrietta Lacks’s family has denounced the racist medical system that allowed the biotech company to make billions in profit from the “HeLa” cell line, which helped produce remedies for multiple diseases, including the first polio vaccine. Details of the settlement were not made public, but the plaintiffs celebrated the lawsuit’s resolution last Tuesday, on Henrietta Lack’s birthday. For more on the case and the history of medical racism in the United States, we speak with Dorothy Roberts, director of the University of Pennsylvania Program on Race, Science and Society. She is the author of several books, including Fatal Invention: How Science, Politics, and Big Business Re-create Race in the Twenty-first Century. “What happened to Henrietta Lacks didn’t just happen to her. It’s part of a long history of experimentation and exploitation of Black people in biomedical research,” says Roberts...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024